Materials Today Bio
Cure8 research brief
Limited source text
What Cure8 can confirm
What We Know
Cure8 does not have enough reliable source text to summarize this article yet. Based on the article title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, Microbiome, and Research and clinical trials. Use the original source link for the full details.
What Is Not Available
The source did not provide enough reliable article text for a source-grounded Cure8 brief. Study details, results, and limitations should be checked in the original source.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationMaterials Today Bio
PublisherElsevier BV
AuthorsMeng Li, Xiaomeng Yue, Qiangwei Liu +8 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedAug 1, 2026, 12:00 AM
Content availableMetadata only
Funding disclosed by the source: Tianjin Municipal Education Commission, award 2023ZD020; Tianjin Science and Technology Program, award 23JCYBJC01760; Natural Science Foundation of Tianjin Municipality; Natural Science Foundation of Tianjin Science and Technology Correspondent Project, award 25JCZDJC00750
Cure8 could not retrieve enough reliable source text to summarize this article. This page is based on the article title, source metadata, and Cure8 topic classification.
Effects of cuproptosis and its application in inflammatory bowel disease (Review).
Researchers report links between copper-driven cell death pathways and IBD biology; identifying cuproptosis-related biomarkers or drugs could open new diagnostic or therapeutic avenues for people with Crohn's disease or...
Synergistic synbiotic therapies for ulcerative colitis: mechanistic insights from multi-targeted pathways in animal models
People with ulcerative colitis may be interested because synbiotic approaches aim to change the gut microbiome and intestinal barrier and therefore could become a future therapeutic option or adjunct. The paper...
Lactobacillus johnsonii mediates the protective effects of pristimerin against ulcerative colitis and concomitant liver injury through remodeling hepatic lipid metabolism via LXRα-SCD1 axis.
The study identifies a gut bacteria–liver signaling axis (Lactobacillus johnsonii → hepatic LXRα–SCD1) that may explain how altered hepatic lipids contribute to UC and related liver injury, and shows pristimerin can...